Screener
Theravance Biopharma TBPH Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $20.73M-20.9% | $17.7M+15.0% | $45.89M+145% | $19.99M+18.5% | $26.2M+83.7% | ||
| $4.71M-55.1% | $5.83M-49.1% | $7.36M-22.1% | $8.11M-12.5% | $10.49M+5.4% | ||
| $14.18M-23.1% | $17.72M-3.5% | $18.52M+0.1% | $18.33M+8.6% | $18.43M+8.1% | ||
| $29.01M+0.3% | $27.18M-8.9% | $25.88M-7.4% | $26.45M-4.5% | $28.92M-3.5% | ||
| -$8.28M-204% | -$9.48M+34.3% | $20.01M+318% | -$6.46M+40.4% | -$2.73M+82.6% | ||
| -39.9%-29.5pp | -53.6%+40.2pp | 43.6%+92.7pp | -32.3%+32.0pp | -10.4%+99.8pp | ||
| —— | —— | $582K-9.5% | $573K-9.0% | $663K+3.0% | ||
| $3.49M+139% | $3.01M+221% | $3.64M+303% | $4.14M+193% | $1.46M+29.2% | ||
| -$4.79M-107% | -$6.47M+54.2% | $73.07M+917% | -$2.89M+71.3% | $73.21M+581% | ||
| $1.11M-94.0% | -$1.54M-175% | $12.04M+82.8% | -$6.5M-346% | $18.37M+1,305% | ||
| -$5.9M-111% | -$4.93M+63.7% | $61.02M+493% | $3.62M+128% | $54.84M+432% | ||
| -28.5%-238pp | -27.9%+60.4pp | 133%+216pp | 18.1%+93.4pp | 209.3%+325pp | ||
| -$0.11-110% | -$0.10+63.0% | $1.15+471% | $0.07+127% | $1.08+418% | ||
| -$7.91M-242% | -$9.1M+35.1% | $20.41M+333% | -$6.05M+41.9% | -$2.32M+84.8% | ||
| -38.2%-29.3pp | -51.4%+39.7pp | 44.5%+91.3pp | -30.3%+31.4pp | -8.8%+98.3pp | ||
| -$8.28M-204% | -$9.48M+34.3% | $20.01M+318% | -$6.46M+40.4% | -$2.73M+82.6% |
FAQ
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $104.3M in revenue over the trailing twelve months, up 35.1% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $53.8M in net income over the trailing twelve months, a 51.6% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is -4.0%, with a 51.6% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $1.01.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
